Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Tracon Pharmaceuticals, Inc. (TCON)
Sector: Healthcare; Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2022-01-28 Opaleye Management Inc. 10%-Owner Buy 500 $2.20 $1,100 No
2022-01-24 Opaleye Management Inc. 10%-Owner Buy 52,363 $2.15 $112,414 No
2022-01-20 Opaleye Management Inc. 10%-Owner Buy 45,000 $2.25 $101,032 No
2021-12-29 Opaleye Management Inc. 10%-Owner Buy 52,325 $2.51 $131,362 No
2021-12-15 Opaleye Management Inc. 10%-Owner Buy 21,964 $2.43 $53,287 No
2021-12-14 Opaleye Management Inc. 10%-Owner Buy 57,204 $2.56 $146,498 No
2021-12-06 Opaleye Management Inc. 10%-Owner Buy 112,007 $2.29 $256,385 No
2021-12-02 Opaleye Management Inc. 10%-Owner Buy 60,500 $2.39 $144,820 No
2020-12-22 Opaleye Management Inc. 10%-Owner Buy 496,277 $8.06 $3,999,993 No
2020-10-21 Opaleye Management Inc. 10%-Owner Buy 8,656 $4.40 $38,060 No
2020-09-24 Opaleye Management Inc. 10%-Owner Buy 78,734 $4.73 $372,095 No
2020-09-09 Opaleye Management Inc. 10%-Owner Buy 56,558 $3.38 $190,902 No
2020-09-02 Opaleye Management Inc. 10%-Owner Buy 159,800 $2.28 $363,825 No
2020-08-31 Opaleye Management Inc. 10%-Owner Buy 545,504 $1.74 $950,378 Yes

Insider Smart

Planet Fitness, Inc (PLNT) - Our position in PLNT is also inspired by insider trading, if insiders are comfortable and confident buying around $50, it is an easy hold if you can pick it up at an even lower price. Our avg cost of the position is ~$40 and is now with 50% profit.

Insider Smart

MGM Resorts International (MGM) - If we were to pick one of the easy trade from the crash, it has to be MGM, checkout the impressive insider buying after crash. Do you really need more confidence to pull the trigger? That's the mental edge you need to work against fear.